The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?

作者: J Thomas Cox

DOI: 10.1097/01.GCO.0000216315.72572.FB

关键词:

摘要: Human papillomavirus (HPV) is a significant health care burden in the United States. The majority of sexually active men and women will be infected with HPV at some point their lives are subject to developing human papillomavirus-associated disease. Current estimates suggest that 20 million Americans currently infected, more than 5 new infections occur each year. prevalence highest populations late teens early twenties, nearly half all occurring within 3 years first intercourse. necessary cause genital warts, cervical intraepithelial neoplasia, invasive cancer. As such, responsible for medical morbidity costs. Screening cytology has significantly reduced mortality rates; however, approximately 3900 die 2005 from cancer DNA testing shown promise identifying high-grade abnormalities as an adjunct traditional cytology, should used according guidelines established by American Cancer Society College Obstetricians Gynecologists. epidemiology infection brief introduction natural history presented here.

参考文章(97)
Sillman Fh, Fruchter Rg, Boyce Jg, Butt K, Sedlis A, Halpert R, Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstetrics & Gynecology. ,vol. 68, pp. 251- 258 ,(1986)
Murad Alam, Matthew Stiller, Direct medical costs for surgical and medical treatment of condylomata acuminata. Archives of Dermatology. ,vol. 137, pp. 337- 341 ,(2001) , 10.1001/ARCHDERM.138.4.533
Frederick H Sillman, Stephen Sentovich, David Shaffer, Ano-Genital Neoplasia in Renal Transplant Patients Annals of Transplantation. ,vol. 2, pp. 59- 66 ,(1997)
LAURA A. KOUTSKY, DENISE A. GALLOWAY, KING K. HOLMES, EPIDEMIOLOGY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION Epidemiologic Reviews. ,vol. 10, pp. 122- 163 ,(1988) , 10.1093/OXFORDJOURNALS.EPIREV.A036020
F. X. Bosch, S. de Sanjose, Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. Journal of The National Cancer Institute Monographs. ,vol. 2003, pp. 3- 13 ,(2003) , 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A003479
Gillian D. Sanders, Al V. Taira, Cost Effectiveness of a Potential Vaccine for Human papillomavirus Emerging Infectious Diseases. ,vol. 9, pp. 37- 48 ,(2003) , 10.3201/EID0901.020168
A. Ferenczy, C. Bergeron, R.M. Richart, Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. International Journal of Gynecology & Obstetrics. ,vol. 32, pp. 291- 291 ,(1990) , 10.1016/0020-7292(90)90371-Q
Laura Koutsky, PhD, Epidemiology of Genital Human Papillomavirus Infection The American Journal of Medicine. ,vol. 102, pp. 3- 8 ,(1997) , 10.1016/S0002-9343(97)00177-0
C Clavel, M Masure, J-P Bory, I Putaud, C Mangeonjean, M Lorenzato, R Gabriel, C Quereux, P Birembaut, Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women British Journal of Cancer. ,vol. 80, pp. 1306- 1311 ,(1999) , 10.1038/SJ.BJC.6690523